Oregon State Drug Review


A monthly newsletter published by the College of Pharmacy on behalf of the OHA. Provides drug utilization reviews, drug and therapeutic guideline reviews, and cost-effective prescribing recommendations to Medicaid providers and pharmacies throughout Oregon. Each newsletter is offered in PDF format for viewing and printing.

You may elect to receive the newsletter monthly via email subscription through the OSUPHARMDI Listserv.

Volume 14 - 2024

Issue Table of Contents
No. 7, July 2024 Lifestyle Modifications for Obesity: Recommendations and Benefits
No. 6, June 2024 Critical Access Pharmacy Programs
No. 5, May 2024 Safety Risks Associated with Long-Term Use of Proton Pump Inhibitors
No. 4, April 2024 Medication Holidays
No. 3, March 2024 Asthma Relief Inhaler Drug Use Evaluation
No. 2, February 2024 Hepatitis C Care for Primary Care Providers
No. 1, January 2024 Updates for Insomnia: Evidence and Oregon Medicaid Policy

 

Volume 13 - 2023

Issue Table of Contents
No. 9, December 2023 Opioid Reversal Agents
No. 8, November 2023 Prevention of Respiratory Syncytial Virus (RSV) Infection: New Products and Recommendations
No. 7, September 2023 An Update in Weight Loss Therapies - Including FDA Approved GLP-1 Receptor Agonists
No. 6, August 2023 2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on Revised Recommendations for Inhaler Products
No. 5, July 2023 Update on the Use of SGLT-2 Inhibitors
No. 4, May 2023 Buprenorphine: Place in Therapy for Chronic Pain
No. 3, April 2023 COVID-19 Therapeutics Update: Where Are We Now? (Evidence updated through March 31, 2023)
No. 2, February 2023 Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescription - *Correction to Previous Posting
No. 1, January 2023 Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Benefit for Children and Adolescents

 

Volume 12 - 2022

Issue Table of Contents
No. 9, November 2022 Hormone Replacement Therapy – A Focus on the Benefits and Risks of Estrogen
No. 8, October 2022 Pharmacological Prevention and Treatment of Monkeypox
No. 7, September 2022 COVID-19 Vaccine Bivalent Boosters
No. 6, August 2022 An Update in Lipid Lowering Therapies
No. 5, July 2022 Antimicrobial Stewardship
No. 4, May 2022 Population Trends in the Use of Migraine Preventative Treatments
No. 3, April 2022 Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma
No. 2, March 2022 Updated 2021 Treatment Guidelines for Sexually Transmitted Infections
No. 1, January 2022 Second-Generation Antipsychotic Use in Children and Adolescents

 

Volume 11 - 2021

Issue Table of Contents
No. 9, December 2021 A PEP Talk on PrEP-ing for HIV Prevention
No. 8, November 2021 Anti-SARS-CoV-2 Therapeutics can Effectively Treat, Prevent COVID-19 Infection
No. 7, September 2021 Updates in Heart Failure Therapy: New Drugs and Indications
No. 6, August 2021 Therapeutic Uses for Cannabinoids
No. 5, July 2021 Deprescribing Techniques to Minimize Safety Issues Associated with Inappropriate Polypharmacy
No. 4, May 2021 COVID-19 Vaccine Update
No. 3, March 2021 Bipolar Disorder: Resources for Primary Care Providers
No. 2, February 2021 Antidepressant Review
No. 1, January 2021 Coronavirus Disease-2019 Vaccine Update

 

Volume 10 - 2020

Issue Table of Contents
No. 9, December 2020 2019-2020 Food and Drug Administration Drug Safety Communications Update
No. 8, November 2020 COVID-19 Viral Testing
No. 7, September 2020 Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus
No. 6, August 2020 New Disease-Modifying Anti-Rheumatic Drugs for Management of Rheumatoid Arthritis
No. 5, July 2020 Shifts in the Treatment of Community Acquired Pneumonia
No. 4, May 2020 Optimizing the Use of NPH Insulin in Patients with Type 2 Diabetes Mellitus
No. 3, April 2020 Coronavirus Management: Evidence for Treatment and Drug Shortage Updates
No. 2, March 2020 Biosimilar Medications: Key Considerations for Providers
No. 1, January 2020 Evidence for Drugs that are Heavily Marketed

 

Volume 9 - 2019

Issue Table of Contents
No. 9, December 2019 CGRP Antagonists in Migraine Prophylaxis
No. 8, November 2019 Update on Recent Guidance and Safety Alerts for Opioid Use in Non-cancer Pain
No. 7, September 2019 Pearls and Pitfalls of Clinical Practice Guidelines
No. 6, August 2019 Stimulant Use in Excessive Somnolence Disorders
No. 5, July 2019 Oregon Health Authority Mental Health Clinical Advisory Group (MHCAG) Recommendations for the Treatment of Schizophrenia
No. 4, May 2019 Update on Medications Used to Manage Opioid Use Disorder and Opioid Withdrawal
No. 3, March 2019 Non-statin Low-Density Lipoprotein Cholesterol (LDL-C) Lowering Therapy and Cardiovascular Outcomes
No. 2, February 2019 Benzodiazepine Safety and Tapering
No. 1, January 2019 2017-18 Year in Review: Important Safety Updates

 

Volume 8 - 2018

Issue Table of Contents
No. 7, December 2018 Basal Insulin Update
No. 6, October 2018 Updates on Testosterone Therapy
No. 5, September 2018 Management Strategies for Patients with Prediabetes
No. 4, July 2018 Update on Treatment Options for Moderate to Severe Atopic Dermatitis
No. 3, May 2018 A Review of Implications of FDA Expedited Approval Pathways, Including the Breakthrough Therapy Designation
No. 2, March 2018 Second Generation Antipsychotic Use in Major Depressive Disorder
No. 1, January 2018 What's New with Biologic Agents for Inflammatory Disease?

 

Volume 7 - 2017

Issue Table of Contents
No. 9, December 2017 Current Landscape of the Antidepressant Class: First Line Agents, Newer Agents, and Safety Risks
No. 8, November 2017 Marketing Claims of Newer Drugs and the Evidence
No. 7, August 2017 Oral Anticoagulant Update
No. 6, July 2017 Tramadol and Codeine Use In Pediatrics: A Review of Recent FDA Safety Alerts
No. 5, June 2017 New Biologics for Treatment of Moderate to Severe Psoriasis
No. 4, May 2017 Updates in the Management of Chronic Obstructive Pulmonary Disease
No. 3, April 2017 Management of Opioid Use Disorder
No. 2, March 2017 Non-Analgesics for Pain Management
No. 1, January 2017 Treatment of Gout

 

Volume 6 - 2016

Issue Table of Contents
No. 8, December 2016 Guideline and Policy Updates for Use of Opioids for Non-Cancer Pain and Opioid Use Disorder
No. 7, October 2016 Endocrine Therapy for Breast Cancer
No. 6, August 2016 Vaccine Update 2016
No. 5, July 2016 Pharmacist Prescribed Contraceptives
No. 4, June 2016 Who Benefits from Calcium and Vitamin D Supplementation
No. 3, April 2016 Autism Spectrum Disorder Still Not Linked to the MMR Vaccine: A Review of the Studies since the 1998 Wakefield Study
No. 2, March 2016 Antidiabetic Treatments and Cardiovascular Implications
No. 1, February 2016 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns

 

Volume 5 - 2015

Issue Table of Contents
No. 8, December 2015 Does Sacubitril/Valsartan Pose a Treatment Conundrum for Management of Heart Failure?
No. 7, November 2015 Obesity and Related Sequelae: Are Medications the Answer?
No. 6, October 2015 From Antidotes to Edoxaban: An Oral Anticoagulation Update
No. 5, August 2015 Is Long-Term Proton Pump Inhibitor Treatment for GERD Worth the Risk?
No. 4, June 2015 New Hypertension Guidelines: Do Blood Pressure Goals Need to Change with Age?
No. 3, May 2015 Treating UTIs with the Tried and True
No. 2, March 2015 Combating the Opioid Epidemic: Are Abuse-deterrent Formulations the Answer?
No. 1, February 2015 Evaluation of High Dose SSRI Initiation in Pediatrics and Young Adults

 

Volume 4 - 2014

Issue Table of Contents
No. 8, November 2014 Guidance Update for Prophylaxis of Respiratory Syncytial Virus
No. 7, October 2014 What's New with Oral Anticoagulants?
No. 6, August 2014 New Hepatitis C Antiviral Therapies: How should they be used in clinical practice?
No. 5, June 2014 Update on New Therapies for Treating Major Depressive Disorder (MDD)
No. 4, May 2014 New Cholesterol Guidelines: A Significant Shift in Cholesterol Management
No. 3, April 2014 Second Generation Antipsychotics: Are these drugs effective in treating PTSD?
No. 2, March 2014 Evidence Based Review of Fish Oil: Going Beyond the Headlines
No. 1, January 2014 Strategies for Effective Monitoring and Management of Psychotropics in Children

 

Volume 3 - 2013

Issue Table of Contents
No. 5, November 2013 Update on the New Oral Anticoagulants with a Focus on Apixaban
No. 4, October 2013 Updates and Comparisons of Type 2 Diabetes Treatment Guidelines
No. 3, August 2013 Managing Metabolic Side Effects in Children Receiving Antipsychotics
- Quick Reference Guides
No. 2, July 2013 Updates and Future Perspectives in the Management of Stable Chronic Obstructive Pulmonary Disease
No. 1, April 2013 Management of Gout in the Presence of Chronic Kidney Disease

 

Volume 2 - 2012

Issue Table of Contents
No. 7, December 2012 The Future of Newer Obesity Medications
No. 6, September 2012 Do Spinosad or Ivermectin Have a Place in Head Lice Eradication?
No. 5, August 2012 Triple Therapy with the New Hepatitis C Protease Inhibitors: Challenges and Strategies
No. 4, June 2012 Can The Diabetic War Be Fought By Aggressive Blood Pressure Control?
No. 3, May 2012 Is Prasugrel or Ticagrelor a Better Choice Than the New Generic Clopidogrel?
No. 2, March 2012 Current Findings in the Off-Label Use of Atypical Antipsychotics
No. 1, January 2012 RSV Prophylaxis: Updates and Recommendations

 

Volume 1 - 2011

Issue Table of Contents
No. 1, November 2011 Atypical Antipsychotic Drug Class Review


 

Past Issues of the DUR Board Newsletter:

Click Here

 

About the Oregon State Drug Review

We hope the Oregon State Drug Review newsletter is useful, thought provoking and interesting to our readers. Questions, concerns, comments, or suggestions are always welcome and should be addressed to the managing editor:

Kathy Sentena
OSU College of Pharmacy - Drug Use Research & Management @
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35
Salem, OR 97301-1079
Phone: (503) 947-5220
Fax: 503-947-2596
sentenak @ ohsu.edu